Long-term growth and development in 268 bevacizumab (BEV)-treated and 135 control pediatric/adolescent patients (pts): An integrated analysis.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 10554-10554
Author(s):  
Hermann L. Müller ◽  
Johannes H.M. Merks ◽  
Birgit Geoerger ◽  
Jacques Grill ◽  
Darren Hargrave ◽  
...  

10554 Background: BEV has an established safety profile in adults, but long-term data in children are limited. This analysis examined the effects of BEV on growth/development in pediatric/adolescent pts. Methods: Data (height, weight, body mass index [BMI], bone age data) were pooled (5 trials): NCT00643565 (Ph2/soft tissue sarcoma); NCT01390948 (Ph2/high-grade glioma); NCT00085111 (Ph1/refractory solid tumors); NCT00667342 (Ph2/osteosarcoma); NCT00381797 (Ph2/glioma, medulloblastoma, ependymoma). Pts (<18 yrs old) received ≥1 dose of BEV + chemotherapy (CT) (n=268) or CT alone (n=135). Analyses were exploratory/descriptive. Reference growth data: WHO (<2 yrs); Centres for Disease Control (≥2 yrs). Results: Across the trials, mean number of BEV administrations per pt ranged 5.6–19.9 (dose 5–15mg/kg every 2/3 weeks). Median follow-up time, months (range): BEV+CT, 37.9 (2.4–64.2); CT, 22.9 (2.8–69.2). At baseline, median height, weight, and BMI were close to that of the reference population (mean standard deviation scores [SDS] close to 0). Over 60 months, a slight decline was observed in the mean SDS for height and weight in both arms in this cohort with different tumors/treatments (Table), but remained within normal range of healthy children. Trends were similar for BMI. No delay in growth velocity or bone age in BEV-treated pts vs CT only was observed up to 3 yrs, regardless of age/gender. A subgroup analysis of pts in the growth hormone-dependent development phase was consistent with the overall results. Conclusions: In this analysis, BEV inclusion in the treatment regimen did not have a negative impact on pediatric growth/development beyond that of CT alone. [Table: see text]

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Robert Terziev ◽  
Dimitri Psimaras ◽  
Yannick Marie ◽  
Loic Feuvret ◽  
Giulia Berzero ◽  
...  

AbstractThe incidence and risk factors associated with radiation-induced leukoencephalopathy (RIL) in long-term survivors of high-grade glioma (HGG) are still poorly investigated. We performed a retrospective research in our institutional database for patients with supratentorial HGG treated with focal radiotherapy, having a progression-free overall survival > 30 months and available germline DNA. We reviewed MRI scans for signs of leukoencephalopathy on T2/FLAIR sequences, and medical records for information on cerebrovascular risk factors and neurological symptoms. We investigated a panel of candidate single nucleotide polymorphisms (SNPs) to assess genetic risk. Eighty-one HGG patients (18 grade IV and 63 grade III, 50M/31F) were included in the study. The median age at the time of radiotherapy was 48 years old (range 18–69). The median follow-up after the completion of radiotherapy was 79 months. A total of 44 patients (44/81, 54.3%) developed RIL during follow-up. Twenty-nine of the 44 patients developed consistent symptoms such as subcortical dementia (n = 28), gait disturbances (n = 12), and urinary incontinence (n = 9). The cumulative incidence of RIL was 21% at 12 months, 42% at 36 months, and 48% at 60 months. Age > 60 years, smoking, and the germline SNP rs2120825 (PPARg locus) were associated with an increased risk of RIL. Our study identified potential risk factors for the development of RIL (age, smoking, and the germline SNP rs2120825) and established the rationale for testing PPARg agonists in the prevention and management of late-delayed radiation-induced neurotoxicity.


Author(s):  
Carolina O. Ramos ◽  
Ana P M Canton ◽  
Carlos Eduardo Seraphim ◽  
Aline Guimarães Faria ◽  
Flavia Rezende Tinano ◽  
...  

Abstract Objectives Longer-acting gonadotropin-releasing hormone analogs (GnRHa) have been widely used for central precocious puberty (CPP) treatment. However, the follow-up of patients after this treatment are still scarce. Our aim was to describe anthropometric, metabolic, and reproductive follow-up of CPP patients after treatment with leuprorelin acetate 3-month depot (11.25 mg). Methods Twenty-two female patients with idiopathic CPP were treated with leuprorelin acetate 3-month depot (11.25 mg). Their medical records were retrospectively evaluated regarding clinical, hormonal, and imaging aspects before, during, and after GnRHa treatment until adult height (AH). Results At the diagnosis of CPP, the mean chronological age (CA) was 8.2 ± 1.13 year, and mean bone age (BA) was 10.4 ± 1.4 year. Mean height SDS at the start and the end of GnRHa treatment was 1.6 ± 0.8 and 1.3 ± 0.9, respectively. The mean duration of GnRHa treatment was 2.8 ± 0.8 year. Mean predicted adult heights (PAH) at the start and the end of GnRH treatment was 153.2 ± 8.6 and 164.4 ± 7.3 cm, respectively (p<0.05). The mean AH was 163.2 ± 6.2 cm (mean SDS: 0.1 ± 1). All patients were within their target height (TH) range. There was a decrease in the percentage of overweight and obesity from the diagnosis until AH (39–19% p>0.05). At the AH, the insulin resistance and high LDL levels were identified in 3/17 patients (17.6%) and 2/21 patients (9.5%), respectively. The mean CA of menarche was 12.2 ± 0.5 years. At the AH, PCOS was diagnosed in one patient (4.8%). Conclusions Long-term anthropometric, metabolic, and reproductive follow-up of patients with CPP treated with longer-acting GnRHa revealed effectivity, safety, and favorable outcomes.


Circulation ◽  
2016 ◽  
Vol 133 (5) ◽  
pp. 474-483 ◽  
Author(s):  
Jørgen Videbæk ◽  
Henning Bækgaard Laursen ◽  
Morten Olsen ◽  
Dan Eik Høfsten ◽  
Søren Paaske Johnsen

Author(s):  
L Orosz ◽  
J Lukács ◽  
M Szabó ◽  
T Kovács ◽  
I Zsupán ◽  
...  

Abstract Objectives The aim of this study was to examine the prevalence of major and minor anomalies according to the increase of NT thickness. Methods This is a long-term retrospective study in which singleton gestations of euploid fetuses with increased NT were analyzed. NT measurement was performed in the first trimester examination according to the criteria of fetal medicine foundation (FMF) when the fetal crown-rump length (CRL) was 45 to 84 mm. The cases were followed up from 1 to 5 years postpartum to assess the presence of CHD and to point out other anomalies that could be associated with increased NT. Results The outcome of 133 cases could be analysed out of 198 pregnancies of which in 55 cases some congenital anomalies (minor or major) were revealed up to the 5 years of life (prevalence of 41.4%). The prevalence of CHDs, including the defects of the great vessels, stood out among the others. In the group with NT between 95th and 99th centiles four cases with minor heart problems were identified (11.1%, 4/36). The rate of major cardiac defects proved to be 13.3% (6/45) in the group with NT between 3.5-4.4 mm, and 17.3% (9/52) in the group with NT > 4.5 mm. Among the 35 healthy children with various minor health problems not related to the presence of increased nuchal translucency there were 7 cases with hydrocele. In 3 of them it was associated with unilateral inguinal hernia but in 3 it was isolated and one was part of a complex malformation (The rate of other organ-specific anomalies did not prove to be significant). In the whole study population only thirteen cases (9.8%) ended up in intrauterine death, or arteficial abortion. Conclusion The prevalence of major cardiac defects as well as other major anomalies increases with fetal nuchal thickness. Since the prevalence of CHD is 100 times higher in the population of fetuses with NT above 4.5 mm, specialist fetal echocardiography should be offered in the second trimester together with other follow-up investigations. Among the children without any major abnormalities, a high number of minor anomalies were revealed during the long-term follow-up. These anomalies do not have significant disadvantage to the quality of life, but some of them necessitates short or long-term medical treatment and this should also be leveled with the future parents. Despite the numerous investigations the exact etiology of increased NT remains unknown. The relatively high prevalence of hydrocele in the newborns in our material raises the question wheather it is related to the presence of NT in the fetal period because of abnormal lymphatic development or alterations in the extracellular matrix. Further long-term follow-up studies could probably contribute to find explanation on the etiology of increased NT in the first trimester. These data can be used when counseling parents of euploid fetuses with increased fetal NT.


2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Awat Feizi ◽  
Mahin Hashemipour ◽  
Silva Hovsepian ◽  
Zeynab Amirkhani ◽  
Roya Kelishadi ◽  
...  

Objectives. The aim of the current study was to investigate the growth status of CH, generate specialized growth charts of CH infants, and compare them with their counterparts of regional normal infants. Methods. In this prospective cohort study, 760 (345 girls and 415 boys) neonates born in 2002–2009 diagnosed by neonatal CH screening program in Isfahan were followed up from the time of diagnosis. 552 healthy children were recruited as a control group. The empirical 3rd, 15th, 50th, 85th, and 97th percentiles for height, weight, and head circumference of both sexes were determined and compared with their counterpart values of the control group. The relative frequency of patients with impaired growth for each studied variable was determined. Also, specialized growth charts of CH patients were generated. Results. The percentiles of weight, height, and head circumference of studied patients are significantly different from regional healthy children (P<0.001). The relative frequency of impaired head circumference was decreased to less than 3% at the 3rd year of age and for height it reached gradually 3% and 9% at the 5th year of age for boys and girls, respectively (P<0.05); however for weight still it was statistically more than 3% in both sexes. Conclusion. CH patients had impaired growth development which was improved during follow up, but the catch-up time was earlier for head circumference and later for weight.


Author(s):  
Aadil Beigh ◽  
Bheem Raj Gupta ◽  
Gaurav Sagar ◽  
D. K. Agarwal

Background: The kidney Tx is the treatment of choice for patients with ESRD. However, episodes of AR have a negative impact on short- and long-term graft survival. In spite of immunosuppressive medications, CNI, MMF and steroid, the AR remains a crucial problem for Tx. This analysis was performed to evaluate the changing profile of early AR (during first week of transplant) and its repercussions on graft survival.Methods: This study was an observational cohort study and included 50 renal transplant patients irrespective of age, sex and race who developed bx proven AR within first week of transplant. Three groups were made according to histopathology: ACR, AMR and mixed rejection group. The patients were followed for 6 months thereafter.Results: AR within a week of renal Tx were less symptomatic except decrease in UO. ACR was more common (72%) than AMR and mixed rejections. AMR and Mixed group required more therapeutic modalities than ACR. More patients required HD during AR in AMR and mixed rejection group than ACR. The mean s.cr at 6 months was 1.3,1.5 and 1.6 in ACR, AMR and mixed group respectively. There were more incidences of BK viremia, CMV infection UTI and rejection fronts follow up in AMR and mixed group than ACR group.Conclusions: Acute rejections within a week are less symptomatic and ACR occurred more frequently than AMR and mixed rejection There were more incidences of BKV, CMV and UTI for 6 months follow up in AMR and Mixed rejection group.


Author(s):  
Bruno Bonnechère ◽  
Bart Jansen ◽  
Lubos Omelina ◽  
Victor Sholukha ◽  
Serge Van Sint Jan

Thanks to the evolution of game controllers video games are becoming more and more popular in physical rehabilitation. The integration of serious games in rehabilitation has been tested for various pathologies. Parallel to this clinical research, a lot of studies have been done in order to validate the use of these game controllers for simple biomechanical evaluation. Currently, it is thus possible to record the motions performed by the patients during serious gaming exercises for later analysis. Therefore, data collected during the exercises could be used for monitoring the evolution of the patients during long term rehabilitation. Before using the parameters extracted from the games to assess patients’ evolution two important aspects must be verified: the reproducibility of measurement and a possible effect of learning of the task to be performed. Ten healthy adults played 9 sessions of specific games developed for rehabilitation over a 3-weeks period. Nineteen healthy children played 2 sessions to study the influence of age. Different parameters were extracted from the games: time, range of motion, reaching area. Results of this study indicates that it is possible to follow the evolution of the patients during the rehabilitation process. The majority of the learning effect occurred during the very first session. Therefore, in order to allow proper regular monitoring, the results of this first session should not be included in the follow-up of the patient.


2018 ◽  
Vol 147 ◽  
Author(s):  
D. M. Berendes ◽  
C. E. O'Reilly ◽  
S. Kim ◽  
R. Omore ◽  
J. B. Ochieng ◽  
...  

AbstractGiven the challenges in accurately identifying unexposed controls in case–control studies of diarrhoea, we examined diarrhoea incidence, subclinical enteric infections and growth stunting within a reference population in the Global Enteric Multicenter Study, Kenya site. Within ‘control’ children (0–59 months old without diarrhoea in the 7 days before enrolment,n= 2384), we examined surveys at enrolment and 60-day follow-up, stool at enrolment and a 14-day post-enrolment memory aid for diarrhoea incidence. At enrolment, 19% of controls had ⩾1 enteric pathogen associated with moderate-to-severe diarrhoea (‘MSD pathogens’) in stool; following enrolment, many reported diarrhoea (27% in 7 days, 39% in 14 days). Controls with and without reported diarrhoea had similar carriage of MSD pathogens at enrolment; however, controls reporting diarrhoea were more likely to report visiting a health facility for diarrhoea (27%vs.7%) or fever (23%vs.16%) at follow-up than controls without diarrhoea. Odds of stunting differed by both MSD and ‘any’ (including non-MSD pathogens) enteric pathogen carriage, but not diarrhoea, suggesting control classification may warrant modification when assessing long-term outcomes. High diarrhoea incidence following enrolment and prevalent carriage of enteric pathogens have implications for sequelae associated with subclinical enteric infections and for design and interpretation of case–control studies examining diarrhoea.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2979-2979 ◽  
Author(s):  
Neil A Goldenberg ◽  
Elizabeth Pounder ◽  
R. Knapp-Clevenger ◽  
Marilyn J. Manco-Johnson

Abstract Abstract 2979 Poster Board II-952 BACKGROUND AND OBJECTIVES: Post-thrombotic syndrome (PTS) is an important long-term sequela of deep venous thrombosis (DVT) in children, which may involve the upper or lower venous systems (UVS, LVS). The understanding of pediatric PTS has been limited by variability in outcome measurement, and prospective data are particularly lacking for DVT involving the UVS. Validation data have been published for the performance of a pediatric PTS outcome measure (the Manco-Johnson instrument; Figure 1) in the LVS (Goldenberg et al., Blood 2007). The aims of the present work were to: (1) investigate validity of the Manco-Johnson instrument in the UVS in children, via a cross-sectional derivation cohort/validation cohort design; and (2) preliminarily determine the cumulative incidence of PTS in a prospective inception cohort study of children with DVT affecting the UVS. METHODS AND RESULTS: Validation study: All parameters of the Manco-Johnson instrument were assessed in a derivation cohort (n=78) consisting of healthy children aged 12 months to 21 years who were without personal or first-degree family history of thromboembolism before age 55 years, grouped by age as follows: preschool (12 mo – <6 y; n=30); school age (6 - <13 y, n=28); adolescent (13 – 21 y, n=20). Inter-rater reliability in each parameter of the instrument was evaluated in a mixed validation cohort (n=41) of healthy children and patients with history of DVT affecting the UVS. In the derivation cohort, the upper limit of normal values for contralateral difference in upper limb circumference was 1.0 cm for mid-forearm and mid-upper arm measurements, as calculated by the non-parametric method of Tukey. In addition, dilated superficial collateral veins, venous stasis dermatitis, venous stasis ulcers, and chronic pain of the upper limb, chest or neck that limits activities of daily living or aerobic exercise were all absent among these healthy children. Inter-rater reliability, measured as percent agreement, exceeded 95% for all parameters when applied in the validation cohort by mutually-blinded dual examiners trained in the use of the instrument. Prospective inception cohort study: Inclusion criteria consisted of radiologically confirmed DVT of the subclavian vein, brachiocephalic vein, and/or superior vena cava (SVC), and study enrollment between March 2006 and July 2009. All children underwent comprehensive thrombophilia testing and were managed with anticoagulation in accordance with ACCP pediatric guidelines, for a minimum duration of 3 months. In some cases, acute thrombolytic therapy was instituted based upon clinical decisions. Children were evaluated for PTS using the Manco-Johnson instrument at 3-6 months, 12 months, and annually thereafter in long-term follow-up. Repeat imaging was performed at minimum at 3-6 months post-diagnosis, and if persistent, again at 1 year. Prevalence of PTS was analyzed based upon findings at latest follow-up (minimum 1 year post-diagnosis). Individual patient data on diagnostic findings, treatment, thrombus resolution, and PTS outcome are given in Table 1. Among 13 subjects meeting eligibility criteria, median age at DVT diagnosis was 16 years (range: 2 - 21 years). The SVC was involved in one child. Clinical predisposition consisted of central venous catheterization in approximately 50% of cases and an underlying anatomic vascular abnormality (thoracic outlet syndrome, Paget-Schroetter syndrome) in an additional 23%. Thrombophilia at presentation consisted of elevated factor VIII in 70% and antiphospholipid antibodies in nearly 50%. Thrombolysis was employed in the 2 children with anatomic defects and one with catastrophic antiphospholipid antibody syndrome. DVT persisted following a 3-6 course of anticoagulant therapy in 50% of evaluable patients. The cumulative incidence of PTS at 1-2 years among 7 evaluable patients was 29%, and involved both physical findings and functional impairment (i.e., chronic pain limitation) in each case. CONCLUSIONS: The present findings demonstrate the validity of the Manco-Johnson instrument for pediatric PTS outcome measurement involving the UVS. Using this instrument, PTS appears to be common in children with DVT affecting the UVS, and functionally significant. Broader use of the Manco-Johnson instrument for PTS outcome assessment in prospective studies and clinical trials of pediatric DVT is warranted. Disclosures: Off Label Use: The presentation refers to the use of anticoagulants as a drug class in general in the treatment of venous thromboembolism (VTE) in children. Despite their use in the standard care for pediatric VTE, all anticoagulants remain off-label for this indication in children.


Sign in / Sign up

Export Citation Format

Share Document